首页> 外文期刊>Journal of hepato-biliary-pancreatic surgery >The role of living-donor liver transplantation in surgical treatment for hepatocellular carcinoma.
【24h】

The role of living-donor liver transplantation in surgical treatment for hepatocellular carcinoma.

机译:活体供肝移植在肝细胞癌手术治疗中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/PURPOSE: The role of living-donor liver transplantation (LDLT) in the surgical treatment of patients with hepatocellular carcinoma (HCC) has not been established as yet. METHODS: Preliminary experience gained from 24 patients who underwent LDLT for HCC between March 2002 and November 2004, and the results of the 131 patients who underwent hepatic resection (HR) for HCC between January 1990 and December 2003 were retrospectively analyzed. The exclusion criteria for LDLT for HCC included extrahepatic metastasis and major vascular invasion. RESULTS: (1) LDLT: the median age of the patients was 57 years and the Child-Pugh grades (A/B/C) of the patients were 6, 12, and 6, respectively. The tumor size was 3 cm or less in 15 patients, multinodular tumors were present in 23 patients, and 11 patients (45.8%) met the Milan Criteria. The overall 2-year survival rate was 72.3%, without a significant difference as to whether or not patients met the Milan criteria. (2) HR: on multivariate analysis, the Child-Pugh grade, the presence of cirrhosis, and the number of tumor nodules were considered as independent risk factors for unfavorable survival (P < 0.05). The 84 patients who met the Milan criteria and were Child-Pugh grade A had a 5-year survival rate of 71.3%; this was significantly better than those of the other patients (P < 0.005). Among the 57 patients with intrahepatic recurrence, 18 patients who were Child-Pugh grade A, met the Milan criteria, and were treated by re-resection or ablation therapy achieved a significantly better 5-year survival rate, of 73.1%, as compared to 19.7% in the other 39 patients (P < 0.0045). CONCLUSIONS: HR could be a first-line treatment with a favorable prognosis for patients who have resectable HCC, preserved liver function, and who meet the Milan criteria. Salvage LDLT could be employed in patients with recurrent tumors that cannot be controlled by conventional treatment or in patients in whom liver function has deteriorated to Child-Pugh grade B or C.
机译:背景/目的:活体肝移植(LDLT)在肝细胞癌(HCC)患者的手术治疗中的作用尚未确定。方法:回顾性分析2002年3月至2004年11月间接受LDLT治疗HCC的24例患者的资料,并回顾性分析1990年1月至2003年12月间131例接受肝切除(HR)的患者的结果。肝癌的LDLT排除标准包括肝外转移和主要血管侵犯。结果:(1)LDLT:患者的中位年龄为57岁,Child-Pugh分级(A / B / C)分别为6、12和6。 15例患者的肿瘤大小为3 cm或更小,23例患者存在多结节性肿瘤,11例患者(45.8%)符合米兰标准。 2年总生存率为72.3%,患者是否符合米兰标准没有显着差异。 (2)HR:通过多因素分析,Child-Pugh分级,肝硬化的存在和肿瘤结节的数量被认为是不良生存的独立危险因素(P <0.05)。 Child-Pugh A级符合米兰标准的84位患者的5年生存率为71.3%。这明显优于其他患者(P <0.005)。在57例肝内复发患者中,Child-Pugh A级,符合米兰标准并接受再次切除或消融治疗的18例患者的5年生存率明显提高,为73.1%其他39例患者的19.7%(P <0.0045)。结论:对于可切除的HCC,保留肝功能且符合Milan标准的患者,HR可能是一线治疗,预后良好。 LDLT可用于患有传统治疗无法控制的复发性肿瘤或肝功能恶化至Child-Pugh B级或C级的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号